| pubmed-article:8309811 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8309811 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8309811 | lifeskim:mentions | umls-concept:C0028768 | lld:lifeskim |
| pubmed-article:8309811 | lifeskim:mentions | umls-concept:C0033929 | lld:lifeskim |
| pubmed-article:8309811 | lifeskim:mentions | umls-concept:C0699748 | lld:lifeskim |
| pubmed-article:8309811 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:8309811 | pubmed:dateCreated | 1994-3-11 | lld:pubmed |
| pubmed-article:8309811 | pubmed:abstractText | Recent advances in the pharmacotherapy of obsessive compulsive disorder (OCD) have led to a significant reduction in suffering and a return to productive living for many patients previously considered refractory to treatment. Potent inhibitors of 5-hydroxytryptamine (5-HT) re-uptake clearly have been established as the first-line pharmacotherapy for treatment of OCD. The addition of agents that enhance 5-HT neurotransmission to ongoing treatment in patients whose OCD is refractory to 5-HT re-uptake inhibitors has not yielded impressive results. The addition of dopamine (DA) antagonists to the regimens of treatment-resistant patients appears to be a potentially useful strategy for the specific subgroup of OCD patients with a comorbid chronic tic disorder such as Tourette's syndrome. Pharmacologic studies suggest that both the 5-HT and DA systems may be critical to the treatment and possibly the pathophysiology of OCD. | lld:pubmed |
| pubmed-article:8309811 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8309811 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8309811 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8309811 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8309811 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8309811 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8309811 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8309811 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8309811 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:8309811 | pubmed:issn | 0193-953X | lld:pubmed |
| pubmed-article:8309811 | pubmed:author | pubmed-author:LeckmanJ FJF | lld:pubmed |
| pubmed-article:8309811 | pubmed:author | pubmed-author:PriceL HLH | lld:pubmed |
| pubmed-article:8309811 | pubmed:author | pubmed-author:McDougleC JCJ | lld:pubmed |
| pubmed-article:8309811 | pubmed:author | pubmed-author:GoodmanW KWK | lld:pubmed |
| pubmed-article:8309811 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8309811 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:8309811 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8309811 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8309811 | pubmed:pagination | 749-66 | lld:pubmed |
| pubmed-article:8309811 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8309811 | pubmed:meshHeading | pubmed-meshheading:8309811-... | lld:pubmed |
| pubmed-article:8309811 | pubmed:meshHeading | pubmed-meshheading:8309811-... | lld:pubmed |
| pubmed-article:8309811 | pubmed:meshHeading | pubmed-meshheading:8309811-... | lld:pubmed |
| pubmed-article:8309811 | pubmed:meshHeading | pubmed-meshheading:8309811-... | lld:pubmed |
| pubmed-article:8309811 | pubmed:meshHeading | pubmed-meshheading:8309811-... | lld:pubmed |
| pubmed-article:8309811 | pubmed:meshHeading | pubmed-meshheading:8309811-... | lld:pubmed |
| pubmed-article:8309811 | pubmed:meshHeading | pubmed-meshheading:8309811-... | lld:pubmed |
| pubmed-article:8309811 | pubmed:meshHeading | pubmed-meshheading:8309811-... | lld:pubmed |
| pubmed-article:8309811 | pubmed:meshHeading | pubmed-meshheading:8309811-... | lld:pubmed |
| pubmed-article:8309811 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8309811 | pubmed:articleTitle | The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis. | lld:pubmed |
| pubmed-article:8309811 | pubmed:affiliation | Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut. | lld:pubmed |
| pubmed-article:8309811 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8309811 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8309811 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:8309811 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8309811 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8309811 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8309811 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8309811 | lld:pubmed |
